Meta-Analysis: Acute adverse effects of therapeutic psilocybin doses in treating depression and anxiety – JAMA Netw Open

This meta-analysis examined the acute adverse effects of psilocybin when used in therapeutic doses for treating depression and anxiety. The study analyzed data from six randomized, double-blind clinical trials involving a total of 528 participants. Significant adverse effects identified included headaches, nausea, anxiety, dizziness, and elevated blood pressure, compared to controls. No significant risks of paranoia or transient thought disorder were associated with psilocybin use. Overall, the adverse effects were tolerable and typically resolved within 48 hours, although the study calls for further research into their management.

Reference (link to free full-text):

Akhila Yerubandi et al. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin A Systematic Review and Meta-Analysis. JAMA Network Open, 7(4): e245960. DOI: 10.1001/jamanetworkopen.2024.5960